NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

NASDAQ / LIVE COMPANY INTELLIGENCE

ABVC BioPharma, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERABVC
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ABVC COVERAGE

What’s moving ABVC BioPharma, Inc. now

Current reporting with the operating signal separated from the noise.

01
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders

ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders

Investors are testing whether ABVC BioPharma, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies

ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies

The story matters when it changes ABVC BioPharma, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Cours ABVC BioPharma, Inc.

Cours ABVC BioPharma, Inc.

The story matters when it changes ABVC BioPharma, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement

ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement

The development tests whether ABVC BioPharma, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
05
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

The story matters when it changes ABVC BioPharma, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ABVC filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-12 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-18 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-03-03 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-27 · Period 2026-08-27SEC ↗8-K/AMaterial company eventFiled 2026-08-12 · Period 2026-08-03SEC ↗8-KMaterial company eventFiled 2026-08-04 · Period 2026-08-03SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-09-29 · Period 2026-10-28SEC ↗PRER14AOfficial SEC filingFiled 2026-09-11SEC ↗
EARNINGS / QUARTERLY TRACKER

ABVC BioPharma, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.